Immunologic monitoring during and after OKT3 therapy

C. F. Shield, Douglas Norman

Research output: Contribution to journalArticle

23 Scopus citations

Abstract

Immunologic monitoring should be undertaken during and for 6 weeks after OKT3 treatment. CD3 absolute cell determinations should be obtained three times per week during therapy. A progressive increase of the absolute CD3 cell count above 10/μL is suggestive of an inadequate OKT3 serum level, most often due to an early antimurine response. Weekly posttherapy antimurine response should be determined. The presence or absence of an antimurine response can be suggestive of a successful response to a second therapeutic course of OKT3.

Original languageEnglish (US)
Pages (from-to)120-124
Number of pages5
JournalAmerican Journal of Kidney Diseases
Volume11
Issue number2
Publication statusPublished - 1988

    Fingerprint

ASJC Scopus subject areas

  • Nephrology

Cite this